Article Correctness Is Author's Responsibility: NDA for Novel Relapsing Multiple Sclerosis Oral Treatment Submitted

The article below may contain offensive and/or incorrect content.

Alkermes has submitted a New Drug Application to the FDA for a novel oral fumarate in development to treat relapsing forms of multiple sclerosis.